- Home
- KPRX vs KXIN Comparison
KPRX vs KXIN Comparison
Compare KPRX & KXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- KXIN
- Stock Information
- Founded
- KPRX 1998
- KXIN 2015
- Country
- KPRX United States
- KXIN China
- Employees
- KPRX N/A
- KXIN N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- KXIN Retail-Auto Dealers and Gas Stations
- Sector
- KPRX Health Care
- KXIN Consumer Discretionary
- Exchange
- KPRX Nasdaq
- KXIN Nasdaq
- Market Cap
- KPRX 8.3M
- KXIN 9.0M
- IPO Year
- KPRX N/A
- KXIN N/A
- Fundamental
- Price
- KPRX $3.18
- KXIN $0.92
- Analyst Decision
- KPRX Strong Buy
- KXIN
- Analyst Count
- KPRX 1
- KXIN 0
- Target Price
- KPRX $10.00
- KXIN N/A
- AVG Volume (30 Days)
- KPRX 10.5K
- KXIN 109.1K
- Earning Date
- KPRX 05-09-2025
- KXIN 01-01-0001
- Dividend Yield
- KPRX N/A
- KXIN N/A
- EPS Growth
- KPRX N/A
- KXIN N/A
- EPS
- KPRX 0.87
- KXIN N/A
- Revenue
- KPRX $16,020,000.00
- KXIN N/A
- Revenue This Year
- KPRX N/A
- KXIN N/A
- Revenue Next Year
- KPRX N/A
- KXIN N/A
- P/E Ratio
- KPRX $3.56
- KXIN N/A
- Revenue Growth
- KPRX N/A
- KXIN N/A
- 52 Week Low
- KPRX $2.51
- KXIN $0.64
- 52 Week High
- KPRX $5.76
- KXIN $29.52
- Technical
- Relative Strength Index (RSI)
- KPRX 55.96
- KXIN 49.99
- Support Level
- KPRX $2.64
- KXIN $0.88
- Resistance Level
- KPRX $3.25
- KXIN $1.20
- Average True Range (ATR)
- KPRX 0.19
- KXIN 0.11
- MACD
- KPRX 0.06
- KXIN 0.02
- Stochastic Oscillator
- KPRX 74.32
- KXIN 64.54
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company primarily generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.